Zealand Pharma initiates second Phase 3 trial with dasiglucagon for the treatment of congenital hyperinsulinismGlobeNewsWire • 12/04/19
Total number of shares and voting rights in Zealand Pharma at November 30, 2019GlobeNewsWire • 11/29/19
Notification of managers and closely related parties’ transactions with Zealand Pharma shares in connection with employee warrant programGlobeNewsWire • 11/27/19
Zealand Pharma's (ZEAL) CEO Emmanuel Dulac on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/14/19
Zealand Pharma expands its peptide platform with acquisition of Encycle TherapeuticsGlobeNewsWire • 10/22/19
Total number of shares and voting rights in Zealand Pharma at September 30, 2019GlobeNewsWire • 09/30/19
Zealand Pharma achieves primary and all key secondary endpoints in pediatric Phase 3 trial with dasiglucagon for severe hypoglycemiaGlobeNewsWire • 09/24/19
Zealand Pharma completes subscription of new shares and registration of capital increaseGlobeNewsWire • 09/11/19
Zealand Pharma announces private placement and directed issue of new shares with expected gross proceeds of DKK 559.6 millionGlobeNewsWire • 09/05/19
Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/DiabetesGlobeNewsWire • 09/03/19
Total number of shares and voting rights in Zealand Pharma at August 31, 2019GlobeNewsWire • 08/30/19
Zealand Pharma to attend Morgan Stanley 17th Annual Global Healthcare ConferenceGlobeNewsWire • 08/29/19
Correction: Zealand Pharma appoints Matthew Dallas as new Chief Financial OfficerGlobeNewsWire • 08/28/19
Zealand Pharma A/S (ZEAL) CEO Emmanuel Dulac on First Half 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/15/19
